Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease

Pfizer Inc PFE and Medivation, Inc. MDVN today announced results from the Phase 3 HORIZON trial of the investigational drug dimebon in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination, which measures cognition, or the Clinician's Interview-Based Impression of Change, plus caregiver input, which measures global function.